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Abstract
Background:  An artemisinin-based combination therapy, artesunate (AS) plus sulphadoxine-
pyrimethamine (SP), was compared to SP monotherapy to provide evidence of further treatment options
in southern Mozambique.
Methods: Between 2003 and 2005, 411 patients over one year and 10 kg with uncomplicated Plasmodium
falciparum malaria were randomly allocated SP (25/1.25 mg per kg day 0) or AS/SP (as above plus 4 mg/kg
artesunate days 0, 1 and 2). Allocation was concealed, but treatment was open-label except to
microscopists. The primary objective was the relative risk of treatment failure, which was assessed using
World Health Organization response definitions modified to a 42-day follow-up.
Results: Of the 411 subjects enrolled, 359 (87.3%) completed the follow up period (SP n = 175, AS/SP n
= 184). A survival analysis including 408 subjects showed that the polymerase chain reaction-adjusted cure
rates were 90.4% (95% confidence interval [CI] 84.9%–93.9%) and 98.0% (95% CI 94.8%–99.3%) for SP and
AS/SP respectively. Multivariable analysis showed that treatment with AS/SP decreased the relative hazard
of treatment failure by 80% compared to SP (hazard ratio [HR] 0.2; 95% CI 0.1–0.6) and age over seven
years decreased the relative hazard of failure by 70% (HR 0.3; 95% CI 0.1–0.9), when compared to younger
age. However, having a quintuple dhfr/dhps mutation increased the relative hazard of failure compared to
fewer mutations (HR 3.2; 95% CI 1.3–7.5) and baseline axillary temperature increased the relative hazard
of failure by 50% for each °C increase (HR 1.5; 95% CI 1.1–2.2).
Conclusion: While both treatments were efficacious, AS plus SP significantly decreased the relative
hazard of treatment failure compared to SP monotherapy Artesunate plus sulphadoxine-pyrimethamine,
but not sulphadoxine-pyrimethamine monotherapy, met the current WHO criteria of >95% efficacy for
policy implementation.
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Background
Mozambique (population circa  20,000,000) is a poor
country with a life expectancy of 45 years. Malaria is
responsible for a large health burden, including an esti-
mated 19% of deaths among children under five years of
age [1]. Transmission intensity of the predominantly Plas-
modium falciparum malaria varies throughout the country
according to the season, other environmental factors, and
the use of vector control measures. A treatment policy
with effective anti-malarials is a key component of
malaria control programmes and data regarding resist-
ance of parasites to anti-malarial drugs are now a critical
factor in drug policy decision-making. While chloroquine
was the national policy in Mozambique for the treatment
of uncomplicated malaria as recently as 2003, evidence of
its poor efficacy throughout Africa since the 1980s sig-
nalled a need for alternative anti-malarials [2]. Artemisi-
nin-based combination therapy (ACT) is now generally
considered the best treatment for uncomplicated falci-
parum malaria provided the partner drug is efficacious.
ACT deliverers a more rapid cure compared to non-ACT,
reducing gametocyte carriage (the parasites' sexual stage,
thereby reducing infectivity), and delaying the develop-
ment of anti-malarial resistance [3-5]. The artemisinin
derivative, artesunate (AS), is particularly effective in the
rapid treatment of uncomplicated malaria, and its use in
combination with the longer-acting sulphadoxine-
pyrimethamine (SP) is currently one of four forms of ACT
recommended by the World Health Organization (WHO)
[6,7]. From a programmatic perspective, AS plus SP has
the unique advantage of the full dose of the partner drug
being administered under supervision when malaria is
diagnosed.
There was clear evidence that ACTs substantially reduced
treatment failure, recrudescence and gametocyte carriage
but this had not been reported for Mozambique [8]. How-
ever, amodiaquine plus SP was selected as the national
treatment policy for uncomplicated falciparum  malaria
due to its lower cost. At this time the Ministry of Health
recommended that a phased implementation of an ACT
be studied in parallel in Maputo Province. Efficacy of SP
monotherapy had been assessed by the South East African
Combination Anti-malarial Treatment (SEACAT) evalua-
tion in Namaacha and Matatuine Districts, Maputo Prov-
ince, during 2002 and data showed that a combined
polymerase chain reaction (PCR)-adjusted cure rate
exceeded the 80% level considered for it to be combined
with other anti-malarials to sustain its useful therapeutic
life [7,9]. The prevalence of the quintuple dihydrofolate
reductase (dhfr) and dihydropteroate synthetase (dhps),
mutation across all study sites was 5–6% throughout the
study period [[10], Raman J personal communication].
This randomised controlled trial (RCT) was conducted
during the malaria seasons between 2003 and 2005 to
compare SP with AS plus SP, in order to provide evidence
to health policy makers of further treatment options.
Methods
Study location and design
This multi-centre, open-label, parallel-group RCT was
conducted in Maputo Province, Southern Mozambique in
four public-sector health facilities in two phases: initially
Catuane and Namaacha (2003), thereafter Boane and
Magude (2004–2005) (Figure 1). There had been a
marked decline in malaria prevalence throughout Maputo
Province from 1999 until the time of the study start (Fig-
ure 1). This is attributed to an intensive intervention of
indoor residual spraying (IRS) [11].
Study subjects
Male and non-pregnant, non-breastfeeding female
patients with malaria symptoms, that were older than one
year of age and weighed more than 10 kg, were invited to
give informed consent prior to screening for P. falciparum
infection by rapid diagnostic test (Immunochromato-
graphic Test, P.f®., SA Scientific). Patients diagnosed with
P. falciparum parasitaemia up to 500,000 asexual para-
sites/μml blood (on thick Giemsa-stained smear) and
with axillary temperature greater than or equal to 37.5°C
(or history of fever within the previous 24 hours) were
suitable for inclusion. Patients receiving folate or anti-
malarials (including antibiotics with anti-malarial proper-
ties not used for malaria) within seven days were
excluded. Also excluded were patients with danger signs
(prostration, repeated vomiting and/or dehydration) or
severely ill, those with a history of G6PD deficiency or
allergy to the study (or related) drugs, or those with seri-
ous underlying disease [12,13].
Study treatments, enrolment and follow up
Eligible subjects were randomized to treatment with SP
monotherapy (Fansidar®. Roche, Gauteng, South Africa)
or AS/SP (co-packaged as Arsudar®. Sanofi, Gauteng,
South Africa) (Table 1). Subjects were observed until an
hour post-dose in case a repeat dose was required for vom-
iting. A computerized random allocation schedule was
generated for each site divided sequentially into the three
weight-based dose levels, within which there was an equal
chance of a subject receiving SP or AS/SP. Treatment allo-
cation was concealed from site staff using opaque padded,
sealed envelopes. Subsequently treatments were open-
label, except to microscopists who remained blinded to
treatment allocation.
The visit schedule was based on the WHO protocol for
assessment of in vivo therapeutic efficacy of anti-malarials,
with extension to a 42 day follow-up due to the long elim-
ination half-life of SP [14,15]. After enrolment on day 0,
subjects were asked to return on days 1, 2, 3, 7, 14, 21, 28Malaria Journal 2009, 8:141 http://www.malariajournal.com/content/8/1/141
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Geographical location of the 4 study sites in Maputo Province showing prevalence of malaria at the study start Figure 1
Geographical location of the 4 study sites in Maputo Province showing prevalence of malaria at the study start.Malaria Journal 2009, 8:141 http://www.malariajournal.com/content/8/1/141
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and 42 for assessment of axillary temperature by elec-
tronic thermometer, asexual parasite density (by thick
Giemsa-stained smear from finger-prick sample), haemo-
globin concentration (by finger prick sample,
HemoCue®), clinical signs and symptoms to capture
adverse events, and concomitant medications [16]. A fin-
ger prick sample of blood blotted on filter paper (What-
man No. 1) was also taken at each visit for molecular
analyses. Subjects were considered lost to follow up after
three attempts to contact them by the study team.
Laboratory investigations
Asexual parasite density was calculated using the number
of asexual parasites and assuming 8,000 leukocytes/μl
blood. Genotyping of P. falciparum DNA extracted from
these dried samples based on variations in three highly
variable proteins (merozoite surface proteins 1 and 2, and
glutamine-rich protein) was used to determine if treat-
ment failure was due to a re-infection or recrudescence of
the original infection [17,18]. Infections were classified as
recrudescent if PCR products for all three markers from
day 0 and day of failure parasites were identical. If the
banding patterns for any markers differed between day 0
and day of failure parasites, the infection was classified as
a re-infection. Polymorphisms in the dihydrofolate
reductase, dhfr (codons 51, 59, 108, 164) and dihydrop-
teroate synthetase, dhps (codons 436, 437, 540 and 581)
genes were detected using nested PCR and restriction
endonuclease cleavage [19]. Digestion products separated
on a 2% agarose gel using electrophoresis were visualized
and photographed using a MiniBIS documentation sys-
tem. Genotype of each codon was classified as pure wild,
pure mutant or mixed (both mutant and wild alleles in
one sample).
Data management and analytical methods
The primary study objective was to compare the risk of
treatment failure between the treatment groups, adjusted
for baseline characteristics. A secondary outcome com-
pared the rate of parasite clearance between groups.
Response to treatment was classified according to WHO
definitions for low to moderate malaria transmission
intensity areas, modified for a 42-day follow up [14,15].
Subjects with clinical or parasitological failure, clinical
deterioration other than treatment failure, an adverse
event (AE) requiring treatment withdrawal, allergic reac-
tion during the treatment course, or concomitant pre-
scribing of contra-indicated drugs, were withdrawn and
given rescue treatment with quinine as necessary.
Key fields were verified by a study monitor and double-
entered into an MS Access 2000 (Microsoft Corporation,
Seattle, USA) database. Laboratory data were recorded
electronically. Data were imported into Stata/IC 10.0
(StataCorp LP, College Station, Texas, USA) when out-
comes, time-to-event indicators and explanatory variables
were programmed.
Major protocol violations were defined as subjects: i)
missing days 1, 2, 3 of the ACT arm or days 2,3 of the
monotherapy arm; ii) taking folic acid or a concomitant
medication with anti-malarial activity (cotrimoxazole, tri-
methoprim, chloramphenicol and tetracyclines, with
erythromycin added retrospectively to this list); iii),
whose day 42 visit was more than three days late; and iv)
taking an incorrect dose or repeat dose for vomiting. Data
were not censored for missed visits as it was assumed
intensive AE monitoring would detect malaria symptoms
or treatment. Missing data fields were dropped where
appropriate and subjects lost to follow-up after day 0 were
automatically dropped from the time-to-event analyses.
An attempt was made to follow all subjects to day 42
despite protocol violations.
Sample sizes were calculated assuming an adequate clini-
cal and parasitological response (ACPR) of 75% for SP
and 90% for AS/SP (confidence interval [CI] 95% and
80% power) indicating 100 per treatment group in each
phase of the study (400 subjects in total).
Table 1: Numbers of artesunate 50 mg tablets (4 mg/kg) and sulphadoxine-pyrimethamine 500 mg/25 mg tablets (25/1.25 mg/kg) for 
each weight group
Mass (kg) Approximate age (years) No. of SP tablets (all subjects) No. of AS tablets (AS/SP subjects)
Day 0 Day 0 Day 1 Day 2
10–20 1 – 6 1 1 1 1
21–35 7 – 13 2 2 2 2
> 35 14 + 3 4 4 4
SP: sulphadoxine-pyrimethamine
AS/SP: artesunate/sulphadoxine-pyrimethamineMalaria Journal 2009, 8:141 http://www.malariajournal.com/content/8/1/141
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Time-to-event outcomes, which were considered the most
appropriate for the data, were analysed using Kaplan
Meier (KM) survival methods and Cox's Proportional
Hazards Regression. This allowed data up to the point of
loss to follow-up or withdrawal to be included and for the
relative hazard to approximate the relative risk.
KM distributions and survival curves for the two treatment
groups were compared using a log rank test. Should
model diagnostics suggest hazards were not proportional,
parametric models were applied [20]. Time to treatment
failure was defined as time from day 0 until day of failure
due to recrudescence (early treatment failure [ETF], late
clinical failure [LCF] or late parasitological failure [LPF]).
Time to parasite clearance was time from day 0 to the first
of two consecutive zero parasite density readings. The
analyses were repeated after excluding subjects who had
dose-related protocol violations and censoring the follow-
up for all other protocol violations at the time of their
occurrence.
Ethical issues
The study was approved by the Ethics Committees of the
Mozambican Ministry of Health and the University of
Cape Town prior to commencement, and conducted in
accordance with the South African Clinical Trials Guide-
lines 2000 [21]. Staff members were trained in Good Clin-
ical Practice including how to request informed consent in
the local language. Illiterate patients marked 'X' in the
presence of an independent literate witness who signed
the consent form. Any serious adverse events were
reported to both ethics committees.
Results
Subject disposition is shown in Figure 2. Of 411 subjects
randomized to SP or AS/SP, 359 (87.3%) were followed
to assessment of the study outcome (SP: 175 [87.9%], AS/
SP 184 [86.8%]). The main reason for loss to follow-up
was reportedly movement from the study area, while one
subject in each treatment group was withdrawn for an AE.
There were no differences in baseline and clinical charac-
teristics between treatment groups (Table 2) and protocol
violations were also similar. Three subjects positive
according to rapid diagnostic test and who completed the
study were removed from all analyses as their day 0 slides
were lost prior to parasite density confirmation. Of the
remaining subjects, 27 (SP: 18 [10.3%], AS/SP: 9 [4.9%] p
= 0.054) were rescued for re-treatment of malaria, but
were found by PCR to have been re-infected. Excluding
these re-infections, 138 (88.5%) in the SP arm and 169
(97.7%) in the AS plus SP arm achieved an ACPR (P =
0.0008). The proportion of ETFs was similar between the
two treatment arms but there were significant differences
for all other response categories, including re-infections
(Table 3).
From the survival analysis, Figure 3 illustrates that ACPR
rates were consistently higher in the ACT group compared
to the SP monotherapy group (log-rank p-value =
0.0008). Day 42 success rates were 90.4% (95% CI
84.9%–93.9%) for those taking SP monotherapy and
98.0% (95% CI 94.8%–99.3%) for those taking the ACT.
The multivariate analysis (Table 4) showed the ACT
decreased the relative hazard of failure by 80% compared
to monotherapy, while age over seven years decreased the
relative hazard of failure by 70% compared to younger
age, baseline axillary temperature on Day 0 increased the
relative hazard of failure by 50% for each additional 1°C,
and a quintuple dhfr/dhps mutation increased the relative
hazard of failure 3.2 fold compared to fewer mutations.
The proportional hazard assumption was satisfied overall;
however there was an accelerated time to failure (approx-
imately 6-fold) for subjects with a quintuple mutation
compared to subjects with fewer mutations suggesting
that early treatment failure is particularly associated with
presence of a quintuple mutation. When the analysis was
repeated after excluding or censoring for major protocol
violations (subjects included; SP n = 177 AS/SP n = 177),
results confirmed those found above.
Subject disposition and the analysis dataset Figure 2
Subject disposition and the analysis dataset.
Screened for eligibility (details of non-inclusion not available) 
Artesunate plus 
sulfadoxine-pyrimethamine 
(n=212) 
Total followed to study endpoint 
(n=184, 86.8%) 
Total followed to study endpoint 
(n=175, 87.9%) 
FOLLOW-UP 
RANDOMIZATION 
Sulfadoxine pyrimethamine 
monotherapy (n=199) 
Total (censored if lost to follow-
up, withdrawn or re-infected) 
(n=198, 99.5%) 
Total (censored if lost to follow-
up, withdrawn or re-infected) 
(n=210, 99.1%) 
Excluded from analyses (Day 0 
parasite data lost) (n=1, 0.5%)) 
Withdrawn due to 
AE (n=1 (0.5%)) 
Lost to follow-up 
(n=23, 11.6%) 
Withdrawn due to 
AE (n=1, 0.5%) 
Lost to follow-up 
(n=27, 12.7%) 
Excluded from analyses (Day 0 
parasite data lost) (n=2, 0.9%) 
Total included (n=174, 87.4%)  Total included (n=182, 85.8%) 
CLINICAL/PARASITOLOGICAL 
REPONSE 
SURVIVAL ANALYSIS Malaria Journal 2009, 8:141 http://www.malariajournal.com/content/8/1/141
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Table 2: Baseline and clinical characteristics of all subjects by treatment
Continuous variables SP (n = 199) AS/SP (n = 212) Total (n = 411) p-value
Haemoglobin (g/dL) (mean/SD) 11.0 2.1) 11.4 (2.1) 11.2 (2.1) 0.07*
Temperature (°C) (mean/SD) 37.6 (1.2) 37.4 (1.2) 37.5 (1.2) 0.251*
Dose of pyrimethamine (mg/kg) (mean/SD) 1.7(0.7) 1.8 (0.6) 1.7 (0.6) 0.645*
Dose of artesunate (mg/kg) (mean/SD) N/a 11.4 (3.0) 11.4 (3.0) N/a
Age (years) (median/IQR) 10.0 (5.0–22.0) 12.0 (5.0–24.0) 11.0 (5.0–23.0) 0.237#
Weight (kg) (median/IQR) 25.0 (15.0–52.0) 28.0 (15.0–55.0) 25.8 (15.0–54.0) 0.508#
Parasite density (per μl) (geometric mean/95% CI) 3630.7
(2464.8; 5348.1)
2885.2
(2028.4; 4104.0)
3225.6
(2486.3; 4184.8)
0.284#
Log parasite density (per μl) (median/IQR) 3.8 (2.5–4.5) 3.6 (2.5–4.5) 3.7 (2.5–4.5) 0.315#
Duration malaria symptoms (days) (median/IQR) 1.0 (1.0–3.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 0.347#
Categorical variables (n/%)
Gender male 76 (38) 94 (44) 170 (41) 0.206^
Age 7 years or under 84 (42.2) 79 (37.3) 163 (39.7) 0.306^
Anaemic (haemoglobin < 11 g/dL)1 94 (47) 94 (44) 188 (46) 0.556^
Severely anaemia (haemoglobin < 7 g/dL)1 6 (3) 2 (1) 8 (2) 0.129^
History of vomiting 20 (10) 17 (8) 37 (9) 0.472^
History of vomiting, with fever on day 0 9 (5) 6 (3) 15 (4) 0.361^
Vomited within 1 hour of any dose 7 (4) 12 (6) 19 (5) 0.301^
Diarrhoea in first 24 hrs post dose 14 (7) 7 (3) 21 (5) 0.086^
Diarrhoea between days 2 and 7 7 (4) 5 (2) 12 (3) 0.485^
Quintuple mutation 45/195 (23.1) 39/210 (18.6) 84(20) 0.289^
SP: sulphadoxine-pyrimethamine
AS/SP: artesunate/sulphadoxine-pyrimethamine
1 WHO 2001
N/a Not applicable
* Student's two sample t-tests
#Wilcoxon rank sum test
^Chi-square or Fisher's exact tests
Table 3: Clinical and parasitological response by treatment 
group for subjects completing follow up
Response
n(%)
SP
N = 174
AS/SP
N = 182
Total
N = 356
P*
Re-infection 18 (10.3) 9 (4.9) 27 (7.6) 0.054
Success (ACPR) 138 (88.5) 169 (97.7) 307 (93.3) 0.0008
Treatment failure 18 (11.5) 4 (2.3) 22 (6.7) 0.0008
ETF 5 (3.2) 3 (1.7) 8 (2.4) 0.39
LCF 4 (2.6) 0 4 (1.2) 0.03
LPF 9 (5.8) 1 (0.6) 10 (3.0) 0.006
As patients with re-infection were withdrawn and rescued prior to 
study completion they are excluded form denominators for ACPR 
and treatment failure
SP: sulphadoxine-pyrimethamine
AS/SP: artesunate/sulphadoxine-pyrimethamine
ACPR: adequate clinical and parasitological response
ETF: early treatment failure
LCF: late clinical failure
LPF: late parasitological failure
*2-sample test of proportions
Kaplan-Meier survival curves for time to treatment failure Figure 3
Kaplan-Meier survival curves for time to treatment 
failure.
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The ACT group had faster parasite clearance rates com-
pared to the SP monotherapy group (log-rank p = 0.001)
(Figure 4). Multivariate analysis (Table 5) found that ACT
increased the rate of parasite clearance by 80% compared
with monotherapy. In addition each 10-fold increase in
baseline parasite density decreased parasite clearance by
20%. Subjects from Catuane cleared parasites 80%
quicker compared to those from other sites. A significant
interaction between treatment and parasite density sug-
gested a faster parasite clearance by the ACT compared to
monotherapy at higher parasite densities (HR 1.2; 95% CI
1.0–1.5 p = 0.033). However, the relative hazard of clear-
ing parasites was similar for both treatment groups when
modelled separately, indicating our overall results hold
true for all subjects. The proportional hazard assumption
was satisfied overall and for the treatment and Catuane
effects. The baseline parasite density, however, was found
to amplify the parasite clearance time by approximately
30% for every 10-fold increase. When the analysis was
repeated excluding subjects with dose-related protocol
violations, or censoring at the time of other violations,
results were similar although there were no interactions
identified, and age over seven years (HR 1.3: 95% CI 1.0–
1.7 p = 0.046) was predictive of better parasite clearance
compared to younger age.
Discussion
The aim of this study was to provide evidence to Mozam-
bican health policy-makers regarding efficacy of SP with
or without AS as treatment for uncomplicated malaria. In
a survival analysis, both drug regimens were effective,
however adding artesunate improved outcomes signifi-
cantly with regard to clinical and parasitological cure, and
peripheral parasite clearance time. These results are con-
sistent with the literature, that suggests combining AS
with SP improves efficacy, provided efficacy of SP is suffi-
ciently high [7]. In addition, AS combined with SP
showed an efficacy above 95%, the minimum level rec-
ommended by the WHO for policy implementation. The
increased parasite clearance by the ACT corroborates data
reflecting the higher parasite reduction ratio of the artem-
isinins (approximately 103-105 parasites per asexual life
cycle, compared to 10-103 for SP) [3].
Subjects aged over seven years had a 70% lower risk of
treatment failure than those seven and under, and were
30% more likely to clear parasites faster (the latter associ-
ation was only found when protocol violators were
removed). These findings are consistent with the knowl-
edge that immunity to malaria infection increases with
age [22]. However, this protective effect is not fully under-
stood as there is no clear immunological marker with
which to validate it, and risk factors for malaria are
entwined due to the vector, host and parasite relation-
ships [22-24]. Another possible explanation for associa-
tions between lower age and poorer treatment outcome is
that drug disposition in children may be altered leading to
concentrations below the therapeutic threshold; physio-
logical concentrations of anti-malarials at mg/kg labelled
doses, particularly SP, may be sub-optimal in younger
patients [25,26]. Dosing regimens derived from studies
recruiting adults may lead to inappropriate recommenda-
tions for children particularly if regimens are age-rather
than weight-based, although the former is more practical
in resource-poor environments [27]. Conversely, adults
may be under-dosed if they weigh more than 65 kg [28].
Bearing these findings in mind, healthcare providers
should be trained to monitor children closely, in particu-
lar, for treatment failure.
Table 4: Multivariate model for the relative risk of treatment failure
Variable Hazard ratio 95% CI P
Treatment with AS/SP vs SP 0.2 0.1–0.6 0.004
Age > 7 years vs. age ≤ 7 years 0.3 0.1–0.9 0.033
Presence of a quintuple mutation vs. fewer mutations 3.2 1.3–7.5 0.009
Temperature Day 0 (°C) 1.5 1.1–2.2 0.020
SP: sulphadoxine-pyrimethamine
AS/SP: artesunate/sulphadoxine-pyrimethamine
Kaplan-Meier survival curves for time to parasite clearance Figure 4
Kaplan-Meier survival curves for time to parasite 
clearance.
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Sulphadoxine and pyrimethamine are anti-folates that
inhibit the dihydropteroate synthetase (dhps) and dihy-
drofolate reductase (dhfr) enzymes respectively. Resist-
ance to SP develops due to accumulation of point
mutations in genes that encode these enzymes. The pres-
ence of 5 mutations, 3 in the dhfr gene (S108N/N511/
C59R) and 2 in the dhps gene (A437G/K540E) are associ-
ated with treatment failure [29,30]. This study found pres-
ence of the quintuple mutation was associated with a
more than 3-fold increase in relative hazard of treatment
failure compared to fewer mutations. Similar observa-
tions elsewhere have motivated proposals that molecular
markers of resistance be used to predict future therapeutic
response at the population level due to the myriad factors
playing a role in treatment response [31]. The unexpected
improvement in SP monotherapy cure rates between
2002, and this study's findings, may be explained in the
decreased frequency of quintuple mutations seen in this
province after the replacement of SP monotherapy with
artemether-lumefantrine policy in neighbouring Kwa-
Zulu-Natal (KZN) [10]. However, this mutation fre-
quency is expected to have increased again markedly since
the study was concluded as SP containing regimens have
been implemented country-wide for both the 1st line treat-
ment of uncomplicated malaria (AQ-SP replaced with AS-
SP) and as intermittent preventive treatment for pregnant
women (SP in 2007).
This study showed a significant association between
higher temperature at baseline and greater relative hazard
of treatment failure, as found in other studies [32]. The
biological mechanism for this association is unclear, and
temperature fluctuations, the concomitant use of pyretics
for malaria and the presence other febrile conditions all
indicates body temperature is an inconsistent predictor of
outcome.
Higher parasitaemia at baseline was not found to be an
independent risk factor for treatment failure, as opposed
to findings in other studies, although it was associated
with delayed parasite clearance [33]. The interaction
observed between treatment and parasite density sug-
gested the ACT effect was amplified at higher parasitae-
mias, as would be expected given the specific indication
for artemisinin derivatives in uncomplicated hyperparasi-
taemias [34]. However, this interaction did not translate
into a clear difference between treatments.
This study was able to achieve reasonably good subject
retention and completeness of data in resource-poor com-
munity settings, which have inherent migration risk fac-
tors. Standardized training and methodologies for
outcomes' measurements together with quality control
measures, especially those relating to parasitological end
points, minimized the possibility of measurement error.
While the study was open-label after concealed allocation,
the primary end point was measured by staff blinded to
treatment group. Recrudescence occurred beyond 42 days,
albeit in small numbers, validating this minimum recom-
mended schedule and suggesting that, should resources
allow, follow up be extended further [35].
When data were re-analysed excluding 57 (13.9%) proto-
col violators, results were very similar. Including data
from non-adherent subjects or those taking prohibited
concomitant medications is useful for assessing the effect
of these common practices on treatment response. AS
courses shorter than three days are not recommended due
to their lower efficacy and the increased likelihood of anti-
malarial drug resistance emerging if combined with the
more slowly eliminated SP [5,6]. SP may, however, be suf-
ficient to successfully treat malaria in individual subjects
who take a substantially reduced dose of AS should its
own efficacy be high enough. The study showed that in
90% of subjects SP monotherapy was able to effect an
ACPR. The retrospective addition of erythromycin as a
prohibited drug meant it was the predominant contribu-
tor to this subset of violations (36/43 [83.7%]), however
there was no evidence of erythromycin playing a role in
curing uncomplicated malaria or improving parasite
clearance.
Conclusion
This study found that, while both SP monotherapy and in
combination with AS were effective, the ACT was far supe-
rior, supporting its current use in Mozambique as the
national policy for the treatment of uncomplicated
malaria. However, it is recognized that combinations with
SP may have a limited useful life due to the spread of par-
asite resistance, and inadequate drug levels young chil-
Table 5: Multivariate model for the relative risk of parasite clearance
Variable Hazard ratio 95% CI P
Treatment with AS/SP vs. SP 1.8 1.4 – 2.3 <0.001
Log10 parasite density (per μl) blood) 0.8 0.7 – 0.8 <0.001
Catuane (compared to other sites) 1.8 1.3 – 2.5 <0.001
SP: sulphadoxine-pyrimethamine
AS/SP: artesunate/sulphadoxine-pyrimethamineMalaria Journal 2009, 8:141 http://www.malariajournal.com/content/8/1/141
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dren achieve. It is also possible that SP efficacy has
declined since this study due to the national implementa-
tion of SP as an intermittent preventive treatment policy
for pregnant women during 2007. Of further concern is
the presence of the dhfr 164 mutation, associated with
high-level pyrimethamine resistance found in neighbour-
ing Malawi [36].
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